THE PRESENCE OF VARIOUS POPULATIONS OF CIRCULATING TUMOR CELLS IN THE BLOOD OF BREAST CANCER PATIENTS BEFORE TREATMENT: ASSOCIATION WITH FIVE-YEAR METASTASIS-FREE SURVIVAL

Localized and metastatic tumors are known to lead to the formation of circulating tumor cell (CTC ) clusters in the blood. Currently, there is a heightened interest in the study of molecular and biological characteristics of CTC s. Recent studies have shown the presence of different populations of CTC s in the blood of cancer patients. Some cells are cancer stem cells, some tumor cells undergo epithelial-mesenchymal transition (EMT), and most CTC s do not have features of either stem cells or EMT.

The aim of the study was to evaluate the five-year metastasis-free survival rate in patients with invasive breast carcinoma, depending on the presence of various populations of circulating tumor cells in the blood before treatment.

Material and Methods. A prospective study included 47 patients with newly diagnosed invasive breast cancer (T1–4N0–3M0), who were treated at Cancer Research Institute, Tomsk National Research Medical Center. The patients aged 31 to 69 years. The presence of different populations of CTC s in the blood of patients before treatment was determined by multicolor flow cytometry on the BD FACS Canto system, using different fluorochrome-labeled monoclonal antibodies to EpCam, CD 45, CD 44, CD 24, and N-cadherin. Five-year metastasis-free survival was evaluated by the Kaplan–Meier method. The differences were considered significant at p<0.05.

Results. The results obtained demonstrated that the presence of both stem-like and non-stem CTC s showing signs of EMT with Epcam+CD 45-CD 44-CD 24-Ncadherin+, Epcam+CD 45-CD 44+CD 24-Ncadherin+, and Epcam(m)- CD 45-CD 44+CD 24-Ncadherin+ phenotypes in the blood of breast cancer patients before  treatment reduced the five-year metastasis-free survival rate (p=0.0016, p=0.017 and p=0.011, respectively).

Conclusion. Thus, CTC s in the EMT state are informative for liquid biopsy to assess the risk of hematogenous metastasis and can be considered as targets for selection of personalized chemotherapy. 

1. Kaprin A.D., Starinskiy V.V., Petrova G.V. Malignant neoplasms in Russia in 2018 (morbidity and mortality). Moscow, 2019. 250 р. (in Russian).

2. Yang M.H., Imrali A., Heeschen C. Circulating cancer stem cells: the importance to select. Chin J Cancer Res. 2015 Oct; 27(5): 437–49. doi: 10.3978/j.issn.1000-9604.2015.04.08.

3. Stoecklein N.H., Fischer J.C., Niederacher D., Terstappen L.W. Challenges for CTC-based liquid biopsies: low CTC frequency and diagnostic leukapheresis as a potential solution. Expert Rev Mol Diagn. 2016; 16(2): 147–164. doi:10.1586/14737159.2016.1123095.

4. Zhe X., Cher M.L., Bonfil R.D. Circulating tumor cells: finding the needle in the haystack. Am J Cancer Res. 2011; 1(6): 740–751.

5. Giordano A., Gao H., Anfossi S., Cohen E., Mego M., Lee B.N., Tin S., De Laurentiis M., Parker C.A., Alvarez R.H., Valero V., Ueno N.T., De Placido S., Mani S.A., Esteva F.J., Cristofanilli M., Reuben J.M. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Mol Cancer Ther. 2012 Nov; 11(11): 2526–34. doi: 10.1158/1535-7163.MCT-12-0460.

6. Kaigorodova E.V. Circulating tumor cells: clinical significance in breast cancer (Review). Herald of the Russian Academy of Medical Sciences. 2017; 72(6): 450–457. (in Russian.)]. doi: 10.15690/vramn833.

7. Kaigorodova E.V., Tarabanovskaya N.A., Staheeva M.N., Savelieva O.E., Tashireva L.A., Denisov E.V., Perelmuter V.M. Effect of minor and major surgical injury on the level of different populations of circulating tumor cells in the blood of breast cancer patients. Neoplasma. 2017; 64(3): 437–443. doi: 10.4149/neo_2017_315.

8. Theodoropoulos P.A., Polioudaki H., Agelaki S., Kallergi G., Saridaki Z., Mavroudis D., Georgoulias V. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett. 2010 Feb 1; 288(1): 99–106. doi: 10.1016/j.canlet.2009.06.027.

9. Kasimir-Bauer S., Hoffmann O., Wallwiener D., Kimmig R., Fehm T. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res. 2012 Jan 20; 14(1): R15. doi: 10.1186/bcr3099.

10. Reuben J.M., Lee B.N., Gao H., Cohen E.N., Mego M., Giordano A., Wang X., Lodhi A., Krishnamurthy S., Hortobagyi G.N., Cristofanilli M., Lucci A., Woodward W.A. Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44–CD24lo cancer stem cell phenotype. Eur J Cancer. 2011 Jul; 47(10): 1527–36. doi: 10.1016/j.ejca.2011.01.011.

11. Armstrong A.J., Marengo M.S., Oltean S., Kemeny G., Bitting R.L., Turnbull J.D., Herold C.I., Marcom P.K., George D.J., Garcia-Blanco M.A. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res. 2011; 9(8): 997–1007. doi: 10.1158/1541-7786.MCR-10-0490.

12. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003 Apr 1; 100(7): 3983–8. doi: 10.1073/pnas.0530291100.

13. Kaigorodova E.V., Savelieva O.E., Tashireva L.A., Tarabanovskaya N.A., Simolina E.I., Denisov E.V., Slonimskaya E.M., Choynzonov E.L., Perelmuter V.M. Heterogeneity of Circulating Tumor Cells in Neoadjuvant Chemotherapy of Breast Cancer. Molecules. 2018 Mar 22; 23(4): 727. doi: 10.3390/molecules23040727.

14. Zavyalova M.V., Denisov E.V., Tashireva L.A., Savelieva O.E., Kaigorodova E.V., Krakhmal N.V., Perelmuter V.M. Intravasation as a Key Step in Cancer Metastasis. Biochemistry (Mosc). 2019; 84(7): 762–72. doi: 10.1134/S0006297919070071.

15. Kim M.Y., Oskarsson T., Acharyya S., Nguyen D.X., Zhang X.H., Norton L., Massague J. Tumor self-seeding by circulating cancer cells. Cell. 2009; 139: 1315–26. doi: 10.1016/j.cell.2009.11.025

16. Scatena R., Bottoni P., Giardina B. Circulating tumour cells and cancer stem cells: a role for proteomics in defining the interrelationships between function, phenotype and differentiation with potential clinical applications. Biochim Biophys Acta. 2013; 1835(2): 129–143. doi: 10.1016/j.bbcan.2012.12.002.

17. Asiedu M.K., Ingle J.N., Behrens M.D., Radisky D.C., Knutson K.L. TGFbeta/TNF(alpha)-mediated epithelial- mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype. Cancer Res. 2011 Jul 1; 71(13): 4707–19. doi: 10.1158/0008-5472.CAN-10-4554.

18. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., Brooks M., Reinhard F., Zhang C.C., Shipitsin M., Campbell L.L., Polyak K., Brisken C., Yang J., Weinberg R.A. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4): 704–15. doi: 10.1016/j.cell.2008.03.027.

19. Mego M., Gao H., Lee B. N., Cohen E. N., Tin S., Giordano A., Wu Q., Liu P., Nieto Y., Champlin R.E., Hortobagyi G.N., Cristofanilli M., Ueno N.T., Reuben J.M. Prognostic value of EMT-circulating tumor cells in metastatic breast cancer patients undergoing high-dose chemotherapy with autologous hematopoietic stem cell transplantation. J Cancer. 2012; 3: 369–80. doi: 10.7150/jca.5111.

20. Aktas B., Tewes M., Fehm T., Hauch S., Kimmig R., KasimirBauer S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. 2009. 11(4): R46. doi: 10.1186/bcr2333